



PTO/SB/08b (01-08)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/588,372-Conf. #8452
				Filing Date	August 3, 2006
				First Named Inventor	Kenneth DUNCAN
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	CCI-068US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-5,516,775	05-14-1996	Zimmermann et al.	
	A2*	US-5,958,935	09-28-1999	Davis et al.	
	A3*	US-6,107,301	08-22-2000	Aldrich et al.	
	A4*	US-6,221,873-B1	04-24-2001	Havlicek, Libor, et al.	
	A5*	US-20020019404	02-14-2002	Wang et al.	
	A6*	US-6,417,185	07-09-2002	Goff et al.	
	A7*	US-6,531,479-B2	03-11-2003	Wang et al.	
	A8*	US-6,569,833-B1	05-27-2003	Fahraeus, Robin	
	A9*	US-6,699,854-B2	03-02-2004	Wang, Shudong	
	A10*	US-6,703,395-B2	03-09-2004	Havlicek, Libor	
	A11*	US-20040259894-A1	12-23-2004	Wang et al.	
	A12*	US-20050192300-A1	09-01-2005	Wang et al.	
	A13*	US-6,962,792-B1	11-08-2005	Ball, Kathryn Lindsay	
	A14*	US-20050282843-A1	12-22-2005	Wang et al.	
	A15*	US-20050288307-A1	12-29-2005	Wang et al.	
	A16*	US-7,045,519	05-16-2006	Nuss, John M. et al.	
	A17*	US-20060199830-A1	09-07-2006	Wang et al.	
	A18*	US-20060241297-A1	10-26-2006	Wang et al.	
	A19*	US-20070021419-A1	01-25-2007	Wang et al.	
	A20*	US-20070021452	01-25-2007	Wang et al.	
	A21*	US-20070185134-A1	08-09-2007	Fischer et al.	
	A22*	US-7,262,202	08-28-2007	Fischer et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	EP-0164204-A1	12-11-1985	Fisons plc.		
	B2	EP-0233461-B1	08-26-1987	American Cyanamid Company		
	B3	WO-95/09847-A1	04-13-1995	Ciba-Geigy AG		
	B4	WO-95/09852-A1	04-13-1995	Ciba-Geigy AG		
	B5	EP-0739341-B1	10-30-1996	Novartis AG et al.		
	B6	WO-97/19065-A1	05-29-1997	Celltech Therapeutics Limited		
	B7	WO-00/12485-A1	03-09-2000	Zeneca Limited		
	B8	WO-01/30778-A1	05-03-2001	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.		
	B9	WO-01/60816-A1	08-23-2001	Amgen Inc.		
	B10	WO-01/72745-A1	10-04-2001	Cyclacel Limited		
	B11	WO-02/064586-A2	08-22-2002	Vertex Pharmaceuticals Incorporated		
	B12	WO-02/066480-A2	08-29-2002	Astrazeneca AB		
	B13	WO-02/079193-A1	10-10-2002	Cyclacel Limited		
	B14	WO-02/096905-A1	12-05-2002	Vertex Pharmaceuticals Incorporated		
	B15	WO-03/029248-A1	04-10-2003	Cyclacel Limited		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/588,372-Conf. #8452
				Filing Date	August 3, 2006
				First Named Inventor	Kenneth DUNCAN
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	CCI-068US

B16	WO-04/005283-A1	01-15-2004	Vertex Pharmaceuticals Incorporated	
B17	WO-04/043467-A1	05-27-2004	Cyclacel Limited	
B18	WO-04/043953-A1	05-27-2004	Cyclacel Limited	
B19	WO-04/056368-A1	07-08-2004	Cyclacel Limited	
B20	WO-05/012298-A1	02-10-2005	Cyclacel Limited	
B21	WO-95/19358-A1	07-20-1995	Sandoz-Patent GmbH	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Adams, Jerry L. et al., "Pyrimidinylimidazole Inhibitors of p38: Cyclic N-1 Imidazole Substituents Enhance p38 Kinase Inhibition and Oral Activity," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 11:2867-2870 (2001)		
	C2	Collis, Alan J. et al., "RPR203494 a Pyrimidine Analogue of the p38 Inhibitor RPR200765A with an Improved In Vitro Potency," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 11:693-696 (2001)		
	C3	Paul, Rolf et al., "Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors," <i>J. Med. Chem.</i> , Vol. 36:2716-2725 (1993)		
	C4	Wang, Dai et al., "Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors," <i>J. of Virology</i> , Vol. 75(16):7266-7279 (2001)		
	C5	Zimmermann, Jürg et al., "Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)," <i>Arch. Pharm. Pharm. Med. Chem.</i> , Vol. 329:371-376 (1996)		
	C6	International Search Report for Application No. PCT/GB2005/002134, dated November 30, 2005		
	C7	International Search Report for Application No. PCT/GB2005/000405, dated August 3, 2005		
	C8	Written Opinion for Application No. PCT/GB2004/003282, dated January 30, 2006		
	C9	International Preliminary Report on Patentability for Application No. PCT/GB2004/004465, dated April 24, 2006		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Express Mail Label No. EM 067551977 US Dated: July 29, 2008